ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Business

Indian drugmakers see unique opportunity in biosimilars

Generics producers bet big on a market projected to hit $12.1bn in 2020

A Biocon employee tests drugs in one of the company's pharmaceutical labs. (Courtesy of Biocon)

BANGALORE/NEW DELHI Indian pharmaceutical companies, which dominate the global market for generic drugs, are gearing up for their next big opportunity: developing an innovative class of complex drugs when the original products, which generate sales of up to $60 billion a year, go off patent in advanced industrial economies.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more